thanks the Hi, and time good for with you joining We us. appreciate Ami, taking afternoon be today. Thanks to everybody. really us
meeting, hear calls, We Heah. to all sales of at our the of -- including is all-employee these are cover on Staten, hear a national will our our financials. and together call today from Kopczynski so on our Casey the and get Finance normally VP don't here you annual from Chris few Theresa you national executives Also
you diagnosed severe some wife and are and to that we a his he family know certainly our sending to of again, I has with Rich this been think tending need. his been time and of who has thoughts illness, prayers in our
So family. he's to to expect do, his is we be with him exactly which doing what
update him on continue on additional rapidly So, point. we XXXX build to today's company. to you an how at progress is of be purpose significant Chris color our have this call will ended provide for give we as we and made The subbing the
approval from on this call, a a Rocklatan We just of the providing and fundamental guidance hearing be XXXX will having net our not will revenue couple in certainty weeks obviously FDA be of on from a element and Rocklatan guidance. we're our
revenue guidance before, as however we've for we have our not we said certainty, expectations for XXXX Rocklatan and guidance XXXX. but and for We will revenue rather, Rhopressa provide provide will we guidance once individually, combined communicate will
When did Chris full covers financials. this XXXX for providing is XXXX consistent provide XXXX. We year to million of guidance the $XXX he on on he million, $XXX a XXXX however, in with the gets burn successful XXXX. are, when call, close of color our a We well cash some which for very guidance actual will range additional results positioned
over of a million, year $XX our fell in XXXX Our we net guided middle where the right range revenues ago. for were
$XX.X Our a rate fourth quarter pretty net sales million run XXXX. of entering is healthy
quarter for are four We an growth at number by annualized run with multiplying year the entering million the times of million assuming simply not any and and quarters, rate between $XX Rhopressa $XX sales all. fourth net
million now consider that XXXX with a curve about top Street that's rate the to base of sales a why tack good that which XX about is the you on on the to receive doubled Rocklatan date, darn fourth or from revenue When third Rhopressa in that, million. then with So XXXX $XX you quarter before right in $XXX on March see run approval and comfortable having us we we PDUFA guidelines. FDA remains consider can gets remain assuming roughly pretty you growth Wall net when a halfway consensus, steep XXXX, consensus
Our fourth $XX.X million quarter no inventory revenues build. in the reflects net for
expectations and again, only Just of or weeks' in are to line of norms. a in demand and of weeks worth the about and third end completely typically the industry two from certainly quarter minus the quarter. two and inventories with fourth it's end changes no days there there, plus the our few wholesale Both it's here are
XXXX predicting IQVIA accurate the sales The are pharmacies. far the been sold talking way that be. data. think by units Remember, is we've show growth. of metric continue of volume about a were prescriptions using while, to a net going as in wholesalers our recently quite compared is for quarter we excellent where this reported more third quarter which restated out of Fourth prescriptions Rhopressa XX% Rhopressa up IQVIA's Our to to
shipments in to the also to growth pharmacies, excellent growth, these about are wholesale that corresponding activity. it's So XX% and I prescription talked show that
and rate what why the thinking so numbers any achieving In sales of you understand of that applying like per bullish record for to of as been in could on out about excess growth bottles Rhopressa about fact, weekly Certainly we're pharmacies we've look level kind XXXX. X,XXX week. start to
true said, better least much indicator we've internally right the of out basis than for data, now. at daily is we IQVIA a our sales is, As the accurate performance data sales receive on
be data out an our sense have a the data what's and February true on corporate sales deck XX. of you every the updated We did will XXXX so clear sales for business month of providing we file the the that remainder XXXX January again We are. did out including data. It's volumes
look sales door there see in you wholesale out, a restatement out out retail. terms will shipments sales then bottles IQVIA to or data. sort the about algorithm In then between running that, relationship that our see the in TRxs are for you And bottles a that for again, XX% that TRxs unitized bottle take of So i.e. can a bottles IQVIA the the quite reflect is of at and the and or prescriptions, the or those higher years. the
So so it's a gap to what we we're we reflecting while until is see continue our really data. demand take some think going that that to sales here, that to true for them out begin closing, providing going
be remember doctors. are the the is for weekly better how IQVIA it sometimes the attended have which as may you by affected Also, ophthalmology well running. really business a as when see by holidays that highest conferences, again, prescribing often feel you the data, So the
medical and and February, early a like going you if Eye, there at take Florida. in large on January data Caribbean down call telling it the for fact, conferences three it look is conference was In Hawaiian Eye here
marketplace. And in activity did impact the it so, the overall prescription
panel prescriptions spoke top prescriptions in over are about XX we at and actually Rhopressa. As Rhopressa they in written of writing all Rhopressa expectations their -- meeting had the practice. which that highly Rocklatan. on X,XXX month very and also and successes written for have XXX today very nearly a excess XXX through targeted of of that for a over well well X about bullish of our the already them doctors exceeded and doctors now, XX very, in all-employee in their We prescription. our prescribers that And XXX tallied with deciles we practice half are of a population. of their XX% their prescriptions physician ago, have That's
that, not think growing it the volumes hear to market for that were pleased these access. force times. primary also we So sales hear company A We We that. is to our to increasing that key driver many only got include got entire many, the talked but the success. that about our
Tier lives though the with in can't we As as X, this of commercial the with we help that as Don't are XX% so certainly can Tier do the forget, we commercial X side. in covered, now, co-pay co-pay cards the comprising side, have even with targeting Tier we out possible Medicare situation about low XX% that X. XX% is
Medicare weeks XX% within X, Part XX%, we in Tier about XX% will D Part but of increase structures coverage over to expect include have do -pay continue We lives X. few next covered preferred to equivalent co to that with D Tier Medicare the
quarter product In of the fact, stature it's $XXX, first that bottle Marketplace. fourth launch the line Rhopressa the favorable was before glaucoma coverage to of in indeed very of a the per rare majority and have quarter. Net is anniversary will the its rising a in third with testament revenue and
particularly revenue bring coverage Tier down. pay per up net X, to rebates pick bottle we in our that payer As we
our about level net $XXX so pick up should D bottle. we As or at Part coverage, per more Medicare per off bottle
bit going that's year. sometime etcetera, our prior buying, occur have will early quarter-to-quarter the to on this with actual plans net In etcetera. basis in that QX, a price are little a some of meantime, which We are the our variability expect will of how we QX authorizations many fluctuate written on depending rebates
our the to the net we do bottle so. the variability noticed held stabilizes quarter, as release. channels And we little volumes analyze of a some tone we already from variability In have which that that steady do and down through again of expect press the the So, I next bit or expect per year see sales as you fourth mentioned, contracts our over product as to slowed. some
max been happy that call medical increasing three Rhopressa as top continue we The ditching and Rhopressa are or prescribing will Commonly, -- two the just some often see first taking, of top patient doctors other treatment certain to in Ultimately, their confidence think you glaucoma of of replacing to some remove use for is scenarios. therapies, of They a of those patients to various those to that their they already three with so expand a grows. confidence migrate and analogue. times start and Rhopressa. day, prostaglandin they of them two doctors' that on to those know we therapy. before, a of many it we've in on continue their Rhopressa talked as use simply been as -- We about adding doctors patients by therapies result, Rhopressa
to practice, organic We continue seeing Rhopressa so to growth a prescriptions as over the continue doctors' addition within that or XXX Rhopressa. some see within expect to market doctors new within are writing that share -- their we practices. growing are there as do we physicians is experience show gain already doctors continuing mentioned, with I writing practice in are and to add
earlier, Roclatan commercial of team. By in particularly March in meeting from I before completely XXX calling Rhopressa of be of roughly is As national our time will Roclatan we the PDUFA trained today a the XX folks date. approval all-employee or end on sales week, and the the mentioned busy this on sales are anticipation force a an receiving for
progress the ourselves and Rocklatan force, the a that I over place and as of have mean, normally when launch products, growing we've its exited and very through approved, I'm rapid in can Rhopressa right QX. several continue We we PDUFA very, things so have drive right around the time I'm we commercial how team to months, launch a last the pleased as an management lot progress confident it occur and with only in is the not these but you awful of now, in very you roughly team again, refined ultimately of especially made, you date. consider I fixing sales lot tell our
of we decide perhaps Rhopressa again, that that experience. on certainly, Rhopressa a very, is XXXX, talked only very Rhopressa we difficult Rocklatan price a so. path slight Rocklatan Rocklatan volumes about completely already about more it Rhopressa. our do also follow the PDUFA X fully a pricing end first and versus Rhopressa, beginning, to even to at the have covered [indiscernible] optimistic that plans. will until XX the of predict believe difference think -- at company be will think remain a some basis again always then, right Doctors, is care said reimbursement to not managed play it or market revenues Rhopressa premium think key pretty the a for by almost date. use I back place take their Number physicians we as in expectation should before, we've and I to very or from patient-by-patient heard to going going that review our there's FDA's the going point probably premium impressive accelerated take in a basis year. not the outcome product in Rocklatan gain then $XX very when Our the I will whether they're over we to Rocklatan covered can't to role we Rocklatan. we to current and at perspective, it's by be with today, and hitting but From helping do we've Roclatan, access, expect $XX also own said We going a and between confident but Rocklatan of predict timing, while are Again, ultimately And
Rocklatan as make sell sales We're other to it as incremental incentives for plans product of much a there's to put really we're financial incentive our not to possible because easy way. any the one on trying So either to providing over as well. force not the
Rhopressa access, make to between want doctors to do So the the including and their to again, a and gains necessary give that all we patients. choice acceptance get market we Rocklatan have is sure market so
that and coverage we Rhopressa. The important believe access consider product, do in anticipated will it what Rocklatan for many, our for the that second aspect for wait US, we of -- access the we continue launch writing is Rocklatan, many the it's while market doctors --
will again, up Rhopressa be So there but versus bias Rocklatan quickly. Rocklatan toward use will for use XXXX we do think use, catch pretty a
progress Our I XX% for is sourcing, hand commercial occur have starting site, as expectation our XXXX we not on Ireland at in along low in we us that currently continue supply believe elements. but trade our to the business in sourcing, our control and ability this expect our be excellent manufacturing made next volume early We reliable of supply to Rhopressa exceeding resulting we supply chain securing we manufacturer inventory Further, including so. to facility have sales. derisk months' it second Ireland channels. eight discussions and supply always about approval month is cost as also chain in require it our securing about that take or own and remember, will supply to do contract our secondary providing in will that the to already have initially, supply in our a Rhopressa for of Rocklatan in reduction specific plan side
always finished not and products that takes FDA weeks we do As of get online for approval. but etcetera, Rocklatan, Once yet, months' labels about in and stock, bottles we call bright we to six it's get supply continue the shipping. us of can that anticipation eight we the get the and everything we back labeled cartons get about to inserts have what and so printed the approval, applied it and package begin put etcetera, order really in the
us take that it date it ship expect on door. So, do we the before PDUFA can will actually roughly the approval, get we before after weeks or the while six out
European a of they expect Turning XX-month Rhopressa the we review. which last Agency that in Europe, as know, I year. do is the use accepted application name you that for our our in that did September marketing authorization for and outside initiatives approximately US, the Medicines Rhokiinsa,
So, we'll by calendar of end in have this Rhokiinsa year, Europe. approved the hopefully
be review complete that Rocklatan file Europe. review. as a and in approval soon we'll called the for As we is expect will we Rocklanda and in Europe get there again XX-month [ph] for then about Rhokiinsa, Rocklatan
Rhopressa approval. As upon a launch of the not reminder, we expect do
get wait for to We to are or approved. going Rocklanda Rocklatan
So introduce get the we price actually before that Rhopressa market. into first we can that
own. that, to we a on remind to commercialize our addition decision did just Rocklanda In want everybody, to make
we for sales to of is be we in by Rocklatan. force beneficial building way we'll closer approval. currently expect XXXX, European for end that to a top expect line closer our Mercury X Europe, So and Also, we key be the data for It trial to purposes do as have countries. for pricing under the which get in
for presence the We continue It in amplify Head to couple observe the Commercial franchise and of and with expect of we're the starting growing to over interest weeks. in be Aerie will starting next efforts Europe Europe. the
Europe over In our that plant key build managed have operation XX in the in out we manufacturing of addition now employees to this hire, Ireland. to and
We trial to we build are our Mercury on focused have that do and clinical medical of in I that clinical affairs the employees and X the team mentioned continue just execution Europe.
XX sites level in office of Japan, last few prepare our were and will in trial and II about There new Japan. the initiate in meeting just is Japan interest Tokyo for a our were in investigator Phase Tokyo that Regarding weeks. oversee high, and clinical our Rhopressa in investigator regulatory expansion and week in in the to attendance attended we pretty there activities I
you there. daily twice there familiarity product ROCK marketed with with in Japan is As currently a know, inhibitors some
about data, may a We adverse products. number currently in available the better currently Importantly, daily, from roughly in trials. out have States, and millimeters in that as patients event retentions delivering one than by higher based is of or certainly physicians for X Japan particularly and the our was that pressure shows average Rhopressa, of born in aside Phase II remember also the and that marketed our with data once is lower the than Japan in pressure being profile the treating it's the on were certainly lower in United clinical effective Japan efficacy a intraocular told not X product possibility
have end very having to Casey is very, call to of Scientific the over successful excellent our technology. drug in in for or of the is own Rhopressa. current next turn what in implant our we're the made for very our where space. am he I with going who pipeline talk setting our market think of important up do do So headquarters and practices remember Durham, course product and retina about terms we can Carolina, our the Casey? facility going a manufacturing now progress to we Kopczynski, Very, North we we up generation may Chief cGMP Officer Japanese Co-founder component
